CERo Therapeutics doses second patient in Cohort 2 of Phase 1 CER-1236 trial

Reuters03-30
CERo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> doses second patient in Cohort 2 of Phase 1 CER-1236 trial
  • CERo Therapeutics dosed second patient in Cohort 2 of Phase 1 CER-1236 trial in hematologic malignancies, bringing total treated to five.
  • Safety, pharmacokinetic, pharmacodynamic, and clinical activity monitoring continues, with more than seven days of follow-up completed for Cohort 2 second patient.
  • Prior interim results were presented at February Tandem Meetings, showing no cytokine release syndrome or neurotoxicity of any grade, no dose-limiting toxicities in 28-day window, and in vivo expansion peaking on days 10-14.
  • Clinical observation from one inv(3) AML patient presented in February showed 72 consecutive days of platelet transfusion independence following four infusions over five months at lowest dose.
  • Protocol amendment expands enrollment beyond AML into transfusion-dependent or high-risk MDS, plus post-JAK-inhibitor myelofibrosis, supporting continued dose escalation and planned expansion phase.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603300815PRIMZONEFULLFEED9680211) on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment